ceftriaxone + doxycycline + moxifloxacin

This is a combination of three antibiotics—ceftriaxone, doxycycline, and moxifloxacin—used together for the treatment of severe or resistant bacterial infections.

• Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death.
• Doxycycline is a tetracycline-class antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit in bacteria, preventing the addition of amino acids to growing peptide chains.
• Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair.

This triple combination may be considered in rare cases where broad-spectrum coverage against Gram-positive, Gram-negative, atypical organisms (including Mycoplasma, Chlamydia, Neisseria gonorrhoeae), and resistant pathogens is required—for example in severe community-acquired pneumonia with risk factors for multidrug resistance or complicated pelvic inflammatory disease when standard regimens fail or are contraindicated. However, this specific triple regimen does not appear as a standard recommended therapy in major guidelines; more commonly used combinations include ceftriaxone plus doxycycline (with or without metronidazole) or monotherapy with moxifloxacin.